Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with RET fusion–positive non–small-cell lung cancer (NSCLC). We provide a registrational data set update in more than double (n = 316) of the original re...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Subbiah, Vivek, Gautschi, Oliver, Tomasini, Pascale, de Braud, Filippo, Solomon, Benjamin J., Shao-Weng Tan, Daniel, Alonso, Guzmán, Wolf, Jürgen, Park, Keunchil, Goto, Koichi, Soldatenkova, Victoria, Szymczak, Sylwia, Barker, Scott S., Puri, Tarun, Bence Lin, Aimee, Loong, Herbert, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839260/
https://www.ncbi.nlm.nih.gov/pubmed/36122315
http://dx.doi.org/10.1200/JCO.22.00393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839260/
https://www.ncbi.nlm.nih.gov/pubmed/36122315
http://dx.doi.org/10.1200/JCO.22.00393

Ejemplares similares